Wikipedia (en)
Martin Shkreli (born April 1, 1983) is an Albanian American hedge fund manager and entrepreneur, specializing in healthcare businesses and is a co-founder of MSMB Capital Management, of Retrophin, Inc. and the founder of Turing Pharmaceuticals AG.
He was a co-founder and the Chief Executive Officer of Retrophin LLC, a biotechnology firm founded in 2011.
In September 2015, he was criticized by several public health organizations for obtaining manufacturing licenses on old, out-of-patent, life-saving medicines including pyrimethamine (brand name Daraprim) and increasing the prices of the drugs in the US, sometimes by more than 5000%. Pyrimethamine is listed in the WHO Model List of Essential Medicines, a list of the most important medications needed in a basic health system. He was accused of manipulating the price and taking these basic drugs out of of reach of millions of needy patients worldwide.